MARKET

PEN

PEN

Penumbra
NYSE

Real-time Quotes | Nasdaq Last Sale

279.42
-0.49
-0.18%
After Hours: 279.42 0 0.00% 16:00 06/24 EDT
OPEN
284.47
PREV CLOSE
279.91
HIGH
285.87
LOW
279.13
VOLUME
136.69K
TURNOVER
--
52 WEEK HIGH
320.00
52 WEEK LOW
163.49
MARKET CAP
10.19B
P/E (TTM)
-1687.3188
1D
5D
1M
3M
1Y
5Y
Penumbra nabs FDA clearance for RED 62 reperfusion catheter
Penumbra (PEN) announces FDA 510(k) clearance and commercial availability of the RED 62 Reperfusion Catheter, the latest addition to the company’s Penumbra System. Now available in the U.S., Penumbra’s RED 62
Seekingalpha · 1d ago
Penumbra Receives FDA Clearance for RED 62 Reperfusion Catheter, Enabling Physicians to Address Broad Range of Stroke Patients
ALAMEDA, Calif., June 23, 2021--Penumbra has announced U.S. Food and Drug Administration (FDA) 510(k) clearance and commercial availability of the RED™ 62 Reperfusion Catheter.
Business Wire · 1d ago
Penumbra Wins FDA Clearance for Catheter for Patients With Acute Ischemic Stroke
MT Newswires · 1d ago
Proactive news headlines including Aeris Resources, Blackstone Minerals, Peninsula Energy and Latitude Consolidated
Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:
GlobeNewswire · 1d ago
AtriCure Names Two New Members to the Board of Directors
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors.
Business Wire · 06/15 11:00
Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021
 
Benzinga · 06/04 14:03
Merck spinoff closes higher despite neutral views; Mirati gains on Citi upgrade; more in today’s analyst action
Organon attracts neutral views on the first day of tradingMerck (MRK) spinoff focused on women’s health and biosimilars, Organon (OGN), staged a late-afternoon rally to end ~8.4% higher yesterday on
Seekingalpha · 06/04 12:23
--BTIG Upgrades Penumbra to Buy From Neutral
MT Newswires · 06/04 06:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PEN. Analyze the recent business situations of Penumbra through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PEN stock price target is 315.40 with a high estimate of 335.00 and a low estimate of 291.00.
EPS
Institutional Holdings
Institutions: 364
Institutional Holdings: 33.20M
% Owned: 91.02%
Shares Outstanding: 36.48M
TypeInstitutionsShares
Increased
63
747.97K
New
50
285.02K
Decreased
118
3.43M
Sold Out
41
605.61K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.16%
Healthcare Equipment & Supplies
+0.04%
Key Executives
Chairman/Chief Executive Officer/Director
Adam Elsesser
Chief Financial Officer
Maggie Yuen
Corporate Executive
James Pray
Executive Vice President/General Counsel/Secretary
Johanna Roberts
Executive Vice President
Lynn Rothman
Chief Accounting Officer
Lambert Shiu
Other/Director
Arani Bose
Lead Director/Independent Director
Janet Leeds
Independent Director
Harpreet Grewal
Independent Director
Don Kassing
Independent Director
Bridget O'Rourke
Independent Director
Bridget O'rourke
Independent Director
Surbhi Sarna
Independent Director
Thomas Wilder
No Data
About PEN
Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.

Webull offers kinds of Penumbra Inc stock information, including NYSE:PEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PEN stock methods without spending real money on the virtual paper trading platform.